What’s Wrong with This Picture: Cardax Pharmaceuticals

January 28, 2020

This edition of “What’s Wrong with This Picture?” highlights a pharmaceutical development company that develops and commercializes anti-inflammatory dietary supplements and drugs. The only revenue source, outside of investment funding, is from a synthetic astaxanthin product, Zanthosyn®.  The information below is only a snapshot of the total picture which we encourage you to view more completely as it is a fascinating read if you are interested in this type of discussion. We are not making judgments as to the viability of the company or any investments. Looking at these Financials over the past couple of years has been fascinating to me and I wanted to share.

Website Referenced: https://ir.cardaxpharma.com/all-sec-filings

Trust Transparency Center and I have no economic interest in NAXA. Today, Cardax remains an ongoing enterprise but a number of questions remain. The concerns looked at today are inconsistencies and oddities associated with the financial structure of Cardax and a concern over statements made by Cardax in their financial statements.

Investor Information                                                                                                    

Charts for Cardax Inc (CDXID)

$ 6.50   0.00 (0.00%)     Volume: 106     9:41 AM EST Jan 21, 2020

Based upon this stock valuation Cardax has a Market Cap of $4.46M. On January 15, 2020 Cardax announced a reverse stock split of 200-1. At close of trading January 14, 2020, the stock was trading at $0.048/share down from a reported 52 week high of $50.00/share. This represents a 99% drop in price in less than one year. A new trading symbol after the split indicated an opening price of $9.60/share. At close of trading one week later the CDXID stock closed on January 22, 2020 32% lower at $6.50/share or an equivalent to a pre-split price of $0.0325/share.

After losing approx. $6M in two years:

On January 11, 2019, the Company entered into a $1,000,000 revolving inventory financing facility with a lender that is also a current stockholder that beneficially owns more than 5% of the Company’s common stock. Use of proceeds from this facility is limited to the purchase of inventory, including raw materials, intermediates, and finished goods, unless otherwise waived by the lender. This facility accrues interest at the rate of 12% per annum, is unsecured, and matures in three years from origination. This facility requires monthly interest payments.

On May 20, 2019, the Company entered into a $400,000 promissory note with a lender that is also a current stockholder that beneficially owns more than 5% of the Company’s common stock. On July 10, 2019, this note was amended to increase the principal sum by an additional $100,000. This note accrues interest at the rate of 12% per annum, is unsecured, and originally matured on August 20, 2019, which was subsequently extended to June 30, 2020. All principal and accrued interest is due on the maturity date.


Cardax claims equivalency (i.e., ‘bioidentical’) for the purpose of using existing astaxanthin NDIs and GRAS status, yet the company also claims superiority because they use novel technology to produce synthetic astaxanthin and have provided no evidence that they intend or need to file an NDI .

  • Cardax openly states the ingredient used in Zanthosyn® is DSM AstaSana™.
  • Cardax claims Zanthosyn is 3x better absorbed than other astaxanthin products. DSM makes no similar claims.
  • Cardax points to an undisclosed study population to substantiate these claims. Zanthosyn® has ben repeatedly researched to indicate the AstaSana™ raw material ingredient product is identical to the finished product inside the Zanthosyn® capsule:

The beadlets in ZanthoSyn capsule appear quite similar to (b) “AstaSana 5% CWS beadlets” under microscopic observation. Both astaxanthin beadlets, (a) and (b), contain ca 5% w/w astaxanthin by HPLC assay.

Bloomberg reports the number of Cardax employees to be 12. Cardax does not manufacture Zanthosyn® but relies on an unidentified contract manufacturer to encapsulate the raw material.


Investment raises are more difficult in the dietary supplement industry than most other industries for a number of reasons including the regulatory/non-regulated aspect of our industry and the consistent negative examples of unscrupulous players in this space. Cardax has seemed to find the answer as to how to raise millions of dollars to support a fairly unheard-of dietary supplement. The company likens its ambitions to the track of Lovaza as compared to fish oil supplements. The reality is fish oil is well recognized by consumers and astaxanthin awareness by consumers is estimated at 2%. Awareness by physicians is also low. To be able to develop a following of investors that will allow an accumulated deficit of over $65million is an amazing feat. This is an interesting story to watch develop.

Anthony Reyes
Author: Anthony Reyes

Unlock the Power of Transparency: Schedule a Meeting Now

Ready to Illuminate Your Path?
Partner with Trust Transparency Today.

Get inTouch

Lori Diez

Lori Diez combines compassion and excellence to lead organizations to their next level. A small-town Texas childhood taught her the value of hard work and relationships, which she uses to foster teamwork that brings results that have transformed cultures and programs to their highest potential. Her successful career in pharmaceutical and nutraceutical sales leadership and event hosting has prepared her to deliver results as the COO of TrustTransparency, where she uses her industry knowledge to ensure that the company’s operations run smoothly as they support nutraceutical companies in their mission to help others. Lori’s passion for charity reflects her belief that individuals working together can change the world, no matter how small their contribution to the effort. This year, she looks forward to continuing over a decade of service at the Houston Livestock Show And Rodeo, where she will be the Chairman of the Livestock Committee.

Conference Handouts

Conference Handouts

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 Case Study

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 (1)

Statin Q10 Effect Case Study

Statin Q10 Effect Case Study

Schedule Consultation with Trust Transparency

Glynnda Steinford

Glynnda Steinford, Trust Transparency Consulting’s Director of Customer Relations, brings over four decades of healthcare experience to her vital role in client engagement and relationship building. Her diverse background spans from administering medical groups to impactful stints in pharmaceutical and nutraceutical sales, all underlined by her degree in Healthcare Administration.

At the heart of Glynnda’s work is her talent for nurturing long-term connections, a skill she leverages to enhance client experiences and partnerships within the consultancy. Beyond her professional commitments, she enjoys life’s simple pleasures, whether it’s her love for cats and cooking or her ventures into golf, always prioritizing cherished moments with family and friends. Her personal interests echo the dedication and warmth she extends in her professional network, making her an invaluable asset to the team.

Caiti Dowden

Caiti Dowden stands as a crucial pillar at Trust Transparency Consulting, bringing invaluable insight and expertise to her role as Senior Executive Assistant’ since her start in 2018. With an academic background from Sam Houston University and a career shift from education to the nutraceutical sphere in 2010, Caiti has cultivated a sharp acumen for dissecting industry trends and bolstering strategic decision-making.

Her transition from Data Analyst reflects her growth and deep understanding of the business landscape. Caiti’s commitment goes beyond professional excellence; she thrives on balance, drawing from her rich life outside of work to enhance her organizational contributions. Whether it’s family time, volunteering, or rooting for Houston’s sports teams, she believes in embracing experiences to fuel her professional creativity and insight.

In her current role, Caiti’s dedication to dynamic business analysis and operational support proves her to be an irreplaceable asset to our team, embodying the synergy of personal enrichment and professional success.

Pam Hilpert

Pam Hilpert, Chief of Staff at Trust Transparency Consulting, has been instrumental in the firm since its inception, leveraging her 17 years of accounting experience, including a significant tenure in the nutrition sector. Her collaboration with Scott Steinford spans various successful ventures, emphasizing her integral role in the company’s financial and strategic initiatives.

An alumnus of Sam Houston State University, Pam holds degrees in both Business Administration and Accounting, as well as an MBA, adding academic heft to her practical industry insights. Beyond her professional prowess, Pam is passionate about family, enjoys live music, delves into quilting, and volunteers at her church, reflecting her well-rounded life.

Her multifaceted expertise and longstanding dedication make Pam a cornerstone of Trust Transparency Consulting’s operational strength and team unity.

Scott Steinford

Scott Steinford, a trailblazer in strategic leadership, boasts a certified M&A background, having navigated companies from their genesis to industry prominence. His brainchild, Trust Transparency Consulting, born in 2007, stands as a testament to his dedication to ethical business practices and strategic foresight, offering industry stakeholders invaluable guidance.

Beyond founding and steering companies, Scott has enriched the business landscape with his insightful keynotes and prolific written contributions, emphasizing his commitment to elevating industry standards. His executive tenure shines in roles as CEO or President of for-profits like ZMC-USA and Doctor’s Best, extending to significant contributions in non-profit sectors.

Notably, Scott’s influence is a driving force in the CoQ10 market, where his leadership has significantly bolstered the ingredient’s global presence. His roles in various capacities, including as a New Hope Ambassador, keep the community informed, providing in-depth industry reports and insights.

An active advocate within professional associations and an Editorial Advisor for leading industry publications, Scott’s expertise is both recognized and sought after. With academic roots in Pre-Law and a Master’s in Law, his journey transcends textbooks, embodying real-world business acumen and transformative leadership.

Scott Steinford merges visionary entrepreneurship with principled leadership, creating a legacy of innovation, growth, and unwavering commitment to industry excellence.